stockportfolio.pro
Stocks / CTNM vs EBS
CTNM vs EBS
Contineum Therapeutics, Inc. and Emergent BioSolutions Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Contineum Therapeutics, Inc. (CTNM) | Emergent BioSolutions Inc. (EBS) | |
|---|---|---|
| Market cap | $0.4B | $0.4B |
| Revenue (latest FY) | $0 | $705.20M |
| Net income (latest FY) | $-59.98M | $52.60M |
| Revenue growth (5y CAGR) | — | -14.9% |
| Net margin | — | 7.5% |
| Return on equity | -23.0% | 10.1% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 1 | 7 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open CTNM — free Open EBS — freeFrequently asked questions
Which is bigger, CTNM or EBS?
Contineum Therapeutics, Inc. is larger by market capitalization — $0.4B versus $0.4B.
Which grows faster, CTNM or EBS?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.